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ApoptosisThiazacridine derivatives (ATZD) are a novel class of cytotoxic agents that combine an acridine and thiazoli-
dine nucleus. In this study, the cytotoxic action of four ATZD were tested in human colon carcinoma HCT-8
cells: (5Z)-5-acridin-9-ylmethylene-3-(4-methylbenzyl)-thiazolidine-2,4-dione — AC-4; (5ZE)-5-acridin-9-
ylmethylene-3-(4-bromo-benzyl)-thiazolidine-2,4-dione — AC-7; (5Z)-5-(acridin-9-ylmethylene)-3-(4-chloro-
benzyl)-1,3-thiazolidine-2,4-dione — AC-10; and (5ZE)-5-(acridin-9-ylmethylene)-3-(4-ﬂuoro-benzyl)-1,3-
thiazolidine-2,4-dione — AC-23. All of the ATZD tested reduced the proliferation of HCT-8 cells in a
concentration- and time-dependent manner. There were signiﬁcant increases in internucleosomal DNA
fragmentation without affecting membrane integrity. For morphological analyses, hematoxylin–eosin and
acridine orange/ethidium bromide were used to stain HCT-8 cells treated with ATZD, which presented
the typical hallmarks of apoptosis. ATZD also induced mitochondrial depolarisation and phosphatidylserine
exposure and increased the activation of caspases 3/7 in HCT-8 cells, suggesting that this apoptotic cell
death was caspase-dependent. In an assay using Saccharomyces cerevisiae mutants with defects in DNA
topoisomerases 1 and 3, the ATZD showed enhanced activity, suggesting an interaction between ATZD
and DNA topoisomerase enzyme activity. In addition, ATZD inhibited DNA topoisomerase I action in a
cell-free system. Interestingly, these ATZD did not cause genotoxicity or inhibit the telomerase activity in
human lymphocyte cultures at the experimental levels tested. In conclusion, the ATZD inhibited the DNA
topoisomerase I activity and induced tumour cell death through apoptotic pathways.
© 2013 Elsevier Inc. Open access under the Elsevier OA license.Introduction
Topoisomerases are enzymes that regulate the overwinding or
underwinding of DNA. They relax DNA supercoiling and perform cat-
alytic functions during replication and transcription. There are two
types of topoisomerases: type I enzymes that cleave one strand of
DNA; and type II enzymes that cleave both strands. Both types of
topoisomerases are essential for mammalian cell survival. Therefore,
DNA topoisomerases are important targets for the development of cy-
totoxic agents (Miao et al., 2007; Moukharskaya and Verschraegen,
2012; Pommier et al., 2010; Vos et al., 2011). Topoisomerases I and IIezerra), cpessoa@ufc.br
vier OA license.are important anticancer targets, and topoisomerase inhibitors such
as camptothecin derivatives (e.g., topotecan and irinotecan), which
are used clinically to inhibit the enzymatic activity of topoisomerase I
(type I enzyme), and podophyllotoxin derivatives (e.g., etoposide and
teniposide), which inhibit the enzymatic activity of topoisomerase II
(type II enzyme) (Hartmann and Lipp, 2006) are used to block cancer
growth.
Amsacrine (m-AMSA), an acridine derivative, was the ﬁrst syn-
thetic topoisomerase inhibitor approved for clinical treatment. Al-
though m-AMSA is an intercalator and topoisomerase II inhibitor, its
metabolism has been associated with the production of free radicals,
which may cause serious harm to normal tissues (Belmont et al.,
2007; Blasiak et al., 2003; Ketron et al., 2012; Sebestik et al., 2007).
A number of clinical and experimental studies have demonstrated
that acridine and thiazolidine derivatives are promising cytotoxic
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toxic agents, thiazacridine derivatives (ATZD), that couple the
acridine and thiazolidine nucleus: (5Z)-5-acridin-9-ylmethylene-
3-(4-methylbenzyl)-thiazolidine-2,4-dione (AC-4); (5ZE)-5-acridin-
9-ylmethylene-3-(4-bromo-benzyl)-thiazolidine-2,4-dione (AC-7);
(5Z)-5-(acridin-9-ylmethylene)-3-(4-chloro-benzyl)-1,3-thiazolidin-
e-2,4-dione (AC-10); and (5ZE)-5-(acridin-9-ylmethylene)-3-(4-
ﬂuoro-benzyl)-1,3-thiazolidine-2,4-dione (AC-23). The chemical
structures of these ATZD are illustrated in Fig. 1; their ability to inter-
act with DNA was demonstrated using an electrochemical technique.
These ATZD have demonstrated a solid tumour-selective cytotoxicity
(Barros et al., 2012). Here, we study the mechanism of ATZD's selec-
tive cytotoxicity (AC-4, AC-7, AC-10 and AC-23) in human colon car-
cinoma HCT-8 cells.
Material and methods
The synthesis of thiazacridine derivatives. The chemical data and syn-
thetic procedures for (5Z)-5-acridin-9-ylmethylene-3-(4-methylbenzyl)-
thiazolidine-2,4-dione (AC-4), (5ZE)-5-acridin-9-ylmethylene-3-(4-
bromo-benzyl)-thiazolidine-2,4-dione (AC-7), (5Z)-5-(acridin-9-ylmeth-
ylene)-3-(4-chloro-benzyl)-1,3-thiazolidine-2,4-dione (AC-10) and
(5ZE)-5-(acridin-9-ylmethylene)-3-(4-ﬂuoro-benzyl)-1,3-thiazolidi-
ne-2,4-dione (AC-23) are reported elsewhere (Barros et al., 2012;
Mourão et al., 2005; Silva et al., 2001). Thiazolidine-2,4-dione was
N-(3)-alkylated in the presence of potassium hydroxide, which en-
abled the thiazolidine potassium salt to react with the substituted
benzylhalide in a hot alcohol medium. The thiazacridine derivatives
were synthesised by the nucleophilic addition of substituted 3-
benzyl-thiazolidine-diones on 3-acridin-9-yl-2-cyano-acrylic acid
ethyl ester. The mechanisms of cytotoxic action for the thiazacridine
derivatives were studied as single Z isomers for AC-4 and AC-10.
The AC-7 and AC-23 compounds were studied as isomeric mixtures,
but the Z isomer was the major stereoisomer.
Strains and media for the yeast assays. The Saccharomyces cerevisiae
strains in this study were acquired from Euroscarf (European Saccharo-
myces cerevisiae Archive for Functional Analysis). The following
S. cerevisiae genotypes were used in this study: BY-4741 (MATa; his3Δ
1; leu2Δ 0; met15Δ 0; ura3Δ 0); Top1Δ (YOL006c), same as BY4741
with YOL006c::kanMX4; Top3Δ (YLR234w), same as BY4741 with
YLR234w::kanMX4. The media, solutions and buffers were prepared as
previously described (Burke et al., 2000). Complete medium (YPD),
containing 1% yeast extract, 2% peptone and 2% glucose was used for
routine growth. The stationary-phase cultures were obtained by inocu-
lating an isolated colony into liquid YPD medium and incubating theAC-4
AC-10
Fig. 1. The chemical structures oculture at 28 °C for 72 h with shaking (for aeration). Cultures in the ex-
ponential phase were obtained by inoculating 5×106 cells/ml of the
stationary-phase YPD culture into fresh YPD medium at 28 °C for 2 h.
The cell concentrations were determined in a Neubauer chamber
using a light microscope (LO, Laboroptik GmbH, Bad Homburg, Hessen,
Germany).
Cell lines and cell culture. The cytotoxicity of ATZD was evaluated
using human colon carcinoma HCT-8 cells donated by the Children's
Mercy Hospital, Kansas City, MO, USA. The cells were maintained in
RPMI-1640 medium supplemented with 10% foetal bovine serum,
2 mM glutamine, 100 μg/ml streptomycin and 100 U/ml penicillin.
The cells were kept in tissue-culture ﬂasks at 37 °C in a humidiﬁed at-
mosphere with 5% CO2 and were harvested with a 0.15% trypsin–
0.08% EDTA, phosphate-buffered saline solution (PBS).
The following experimentswere performed to determineATZD's cy-
totoxic mechanisms in HCT-8 cells. For all cell-based assays, the HCT-8
cells were seeded (0.7×105 cells/ml) and incubated overnight to
allow the cells to adhere to the plate surface. Then, the cells were treat-
ed for 12- and/or 24-h at concentrations of 2.5, 5 and/or 10 μg/ml, cor-
responding to: 6.1, 12.2 and 24.4 μM for AC-4; 5.3, 10.6 and 21.2 μM for
AC-7; 5.8, 11.6 and 23.2 μM for AC-10; 6.0, 12.1 and 24.1 μM for AC-23,
respectively. The trypan blue exclusion test was performed before each
experiment described below to assess cell viability. The negative control
was treated with the vehicle (0.1% DMSO) used for diluting the tested
substances. Amsacrine (m-AMSA, 0.3 μg/ml [0.8 μM], Sigma Chemical
Co. St Louis, MO, USA) or doxorubicin (0.3 μg/ml [0.6 μM], Sigma Chem-
ical Co. St Louis, MO, USA) was used as the positive control. The con-
centrations of ATZD used here were based on their IC50 value in this
cell line (3.1 μg/ml for AC-4, 5.3 μg/ml for AC-7, 3.6 μg/ml for AC-10
and 2.3 μg/ml for AC-23) as previously described (Barros et al., 2012).
Trypan blue dye exclusion test. Cell proliferation was determined
using the Trypan blue dye exclusion test. After each incubation peri-
od, the cell proliferation was assessed. Cells that excluded trypan
blue were counted using a Neubauer chamber.
BrdU incorporation assay. Twenty microliters of 5-bromo-20-deoxy-
uridine (BrdU, 10 mM) was added to each well and incubated for 3 h
at 37 °C before 24-h of drug exposure. To assess the amount of BrdU in-
corporated into DNA, cells were harvested, transferred to cytospin
slides (Shandon Southern Products Ltd., Sewickley Pennsylvania,
USA) and allowed to dry for 2 h at room temperature. Cells that
had incorporated BrdU were labelled by direct peroxidase immuno-
cytochemistry using the chromogen diaminobenzidine. The slides
were counterstained with hematoxylin, mounted and put under aAC-7
AC-23
f thiazacridine derivatives.
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termine BrdU-positivity. Two hundred cells per sample were counted
to determine the percent of BrdU-positive cells.
Morphological analyses using hematoxylin–eosin staining. Untreated
or ATZD-treated HCT-8 cells were examined for morphological
changes under a light microscopy (Metrimpex Hungary/PZO-Labimex
Model Studar lab). To evaluate any alterations in morphology, cells
from the cultures were harvested, transferred to a cytospin slide,
ﬁxed with methanol for 30 s, and stained with hematoxylin–eosin.
Morphological analyses using a ﬂuorescence microscope. Cells were
pelleted and resuspended in 25 μl of PBS. Then, 1 μl of aqueous acridine
orange/ethidium bromide solution (AO/EB, 100 μg/ml) was added and
the cells were observed under a ﬂuorescence microscope (Olympus,
Tokyo, Japan). Three hundred cells were counted per sample and classi-
ﬁed as viable, apoptotic or necrotic (McGahon et al., 1995).
Cell membrane integrity. The integrity of the cell membrane was
evaluated using the exclusion of propidium iodide (2 μg/ml, Sigma
Chemical Co. St Louis, MO, USA). Cell ﬂuorescence was determined by
ﬂow cytometry in a Guava EasyCyte Mini System cytometer using
CytoSoft 4.1 software (Guava Technologies, Hayward, California, USA).
Five thousand events were evaluated per experiment and the cellular
debris was omitted from the analysis.
Cell cycle distribution. The cells were harvested in a lysis solution
(citrate 0.1%, triton X-100 0.1% and propidium iodide 50 μg/ml)
(Nicoletti et al., 1991), and the cell ﬂuorescence was determined by
ﬂow cytometry, as described above.
Measurement of the mitochondrial transmembrane potential. The
mitochondrial transmembrane potential was determined by the reten-
tion of rhodamine 123 dye (Gorman et al., 1997; Sureda et al., 1997).
The cells were washed with PBS, incubated with rhodamine 123
(5 μg/ml, Sigma Chemical Co. St Louis, MO, USA) at 37 °C for 15 min
in the dark and washed twice. The cells were then incubated again in
PBS at 37 °C for 30 min in the dark and their ﬂuorescence was mea-
sured by ﬂow cytometry, as described above.
Annexin assay. Phosphatidylserine externalisation was analysed
by ﬂow cytometry (Vermes et al., 1995). A Guava® Nexin Assay Kit
(Guava Technologies, Hayward, CA) determined which cells were ap-
optotic (early apoptotic+late apoptotic). The cells were washed
twice with cold PBS and then re-suspended in 135 μl of PBS with
5 μl of 7-amino-actinomycin D (7-AAD) and 10 μl of Annexin V–PE.
The cells were gently vortexed and incubated for 20 min at room tem-
perature (20–25 °C) in the dark. Afterwards, the cells were analysed
by ﬂow cytometry, as described above.
Caspase 3/7 activation. Caspase 3/7 activity was analysed by ﬂow
cytometry using the Guava® EasyCyte Caspase 3/7 Kit (Guava Tech-
nologies, Hayward, CA). The cells were incubated with Fluorescent
Labelled Inhibitor of Caspases (FLICATM) and maintained for 1 h at
37 °C in a CO2 incubator. After incubation, 80 μl of wash buffer was
added and the cells were centrifuged at 2000 rpm for 5 min. The
resulting pellet was resuspended in 200 μl of wash buffer and
centrifuged. The cells were then re-suspended in theworking solution
(propidium iodide and wash buffer) and analysed immediately using
ﬂow cytometry, as described above.
Drop test assay to determine the sensitivity of mutant S. cerevisiae strains
with defective topoisomerases. The drop test assay determined the
relative sensitivity of different S. cerevisiae strains to ATZD treatment.
The following S. cerevisiae strains were used: BY-4741, Top1Δ and
Top3Δ. Cells were treated with ATZD at concentrations of 50 and100 μg/ml and more, 4 dilutions 1:10 were performed. A suspension
of 2×105 cells/ml of S. cerevisiae in the exponential phase was used.
An aliquot of 3 μl of each dilution was added to plates containing
YEPD medium (YEL+agar). After 3–4 days of growth at 28 °C, the
plates were photographed. m-AMSA served as the positive control.
DNA relaxation assay. The inhibitory effects of ATZD on human DNA
topoisomerase I were measured using a Topo I Drug Screening Kit
(TopoGEN, Inc.). Supercoiled (Form I) plasmid DNA (250 ng) was in-
cubated with human Topo I (4 units) at 37 °C for 30 min in relaxation
buffer (10 mM Tris buffer pH 7.9, 1 mM EDTA, 0.15 M NaCl, 0.1% BSA,
0.1 mM spermidine and 5% glycerol) in the presence or absence of
ATZD (50 and 100 μg/ml, ﬁnal 20 μl). The concentrations used were
based on the positive control indicated in this Kit. CPT (100 μM)
served as the positive control. The reaction was terminated by the
addition of 10% SDS (2 μl) and proteinase K (50 μg/ml) and incubated
at 37 °C for 30 min. The DNA samples were added to the loading dyes
(2 μl) and subjected to electrophoresis on a 1% agarose gel for 90 min
at room temperature and visualised with ethidium bromide.
Assessment of the genotoxic effect in human lymphocytes. A primary
culture was obtained using a standard protocol and a Ficoll gradient.
In addition, phytohemagglutinin (PHA) served as a mitogen to trigger
cell division in T-lymphocytes. Peripheral blood was collected from
four (two women and two men) healthy donors, 19–30 years of age
with no history of smoking/drinking or chronic drug use. Venous
blood (10 ml) was collected from each donor into heparinised
vials. Lymphocytes were isolated with a Ficoll density gradient
(Histopaque-1077; Sigma Diagnostics, Inc., St. Louis). The culture
medium consisted of RPMI 1640 supplemented with 20% foetal bovine
serum, phytohemagglutinin (ﬁnal concentration: 2%), 2 mMglutamine,
100 U/ml penicillin and 100 μg/ml streptomycin at 37 °C with 5% CO2
(Berthold, 1981; Brown and Lawce, 1997; Hutchins and Steel, 1983).
For all of the experiments, cell viabilitywas performed using the Trypan
Blue assay. Ninety percent of the cells had to be viable before starting
the experiments.
Alkaline comet assay. The alkaline (pH>13) version of the comet
assay (Single Cell Gel Electrophoresis) was performed, as described by
Singh et al. (1988) with minor modiﬁcations (Hartmann and Speit,
1997). The slides were prepared in duplicate and 100 cells were
screened per sample (50 cells from each duplicate slide) using aﬂuores-
cencemicroscope (Zeiss) equippedwith a 515–560 nmexcitation ﬁlter,
a 590 nm barrier ﬁlter, and a 40× objective. The cells were visually
scored and sorted into ﬁve classes according to tail length: (1) class 0:
undamaged,without a tail; (2) class 1:with a tail shorter than the diam-
eter of the head (nucleus); (3) class 2:with a tail length 1–2× the diam-
eter of the head; (4) class 3: with a tail longer than 2× the diameter of
the head; and (5) class 4: comets with no heads. A value of damage
index (DI) was assigned to each comet according to its class, using the
formula: DI=(0×n0)+(1×n1)+(2×n2)+(3×n3)+(4×n4), where
n=number of cells in each class analysed. The damage index ranged
from 0 (completely undamaged: 100 cells×0) to 400 (with maximum
damage: 100 cells×4). DI was based on migration length and on the
amount of DNA in the tail and was considered a sensitive measure of
DNA (Speit and Hartmann, 1999).
Chromosome aberration assay. We used naturally synchronised
human peripheral blood lymphocytes with more than 95% of the cells
in the G0 phase (Bender et al., 1988; Wojcik et al., 1996). Short-term
lymphocytes cultures, at a concentration of 0.3×106 cells/ml, were ini-
tiated according to a standard protocol (Preston et al., 1987). ATZDwere
studied at different phases of the cell cycle based on the protocol
described by Cavalcanti et al. (2008)withminormodiﬁcations. Doxoru-
bicin (0.3 μg/ml) served as a positive control. In the experimental pro-
cedures, when ATZD was added after 24-h, cells in both the G1 and S
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Fig. 3. The effect of thiazacridine derivatives on the proliferation of human colon carci-
noma HCT-8 cells. To determine the extent of cell proliferation, inhibition BrdU incor-
poration was determined after a 24-h incubation. The data presented are the mean
values±S.E.M. from three independent experiments performed in duplicate. The
negative control was treated with the same vehicle (NC, 0.1% DMSO) that diluted the
tested substance. Amsacrine (PC, m-AMSA, 0.3 μg/ml) served as the positive control.
*, pb0.05 compared to the negative control using an ANOVA followed by a Student
Newman–Keuls tests.
40 F.W.A. Barros et al. / Toxicology and Applied Pharmacology 268 (2013) 37–46stages were exposed, whilst it can be assumed that when ATZD was
added after 69 h, only cells in the G2 stage were exposed. When ATZD
was added at the same time as the PHA stimulation (in culture start,
0 h), the cells were exposed in the G1 stage. To obtain a sufﬁcient num-
ber of analysable metaphases, colchicine was added at a ﬁnal concen-
tration of 0.0016%, 2 h prior to harvesting. The cells were harvested
by centrifugation, treated with 0.075 M KCl at 37 °C for 20 min,
centrifuged and ﬁxed in 1:3 (v/v) acetic acid:methanol. Finally, the
slides were prepared, air-dried and stained with a 3% Giemsa solution
(pH 6.8) for 8 min (Moorhead et al., 1960).
The slides were analysedwith a light microscope; the structural and
numerical CAs were examined during metaphase in the ATZD-treated
cultures and the respective controls. The frequency of CAs (in 100meta-
phases per culture) and the mitotic index (MI, number of metaphases
per 2.000 lymphocytes per culture) were determined.
Telomerase inhibition assay. The ability of ATZD to inhibit telome-
rase action was measured by determining telomere length using ﬂuo-
rescence in situ hybridisation with probes to telomeric sequences
(TELO-FISH), as described by Lansdorp (1995) and Lansdorp et al.
(1996). Short-term lymphocyte cultures were initiated according to
a standard protocol (Preston et al., 1987) and were ﬁxed (methanol:
acetic acid, 3:1) on slides. The slides were hybridised with the pan
telomeric Star FISH probe. The measurement of telomere length de-
termined in each nucleus, was acquired using the image capturing
software Applied Special Imaging analysis system. The images were
processed using the TFL-TELO software following the protocol (Poon
et al., 1999).
Statistical analysis. The data are presented as the means±standard
error of the mean of n experiments. The differences among experi-
mental groups were compared using a one-way analysis of variance
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Fig. 2. The effect of thiazacridine derivatives on the proliferation of human colon carcinom
trypan blue dye exclusion method after 12- and 24-h incubations, respectively. C and D
propidium iodide after 12- and 24-h incubations, respectively. The data are presented as t
The negative control was treated with the vehicle (NC, 0.1% DMSO) that diluted the test su
tometry analyses, 5000 events were analysed in each experiment. *, pb0.05 compared to thwere carried out using the GRAPHPAD programme (Intuitive Soft-
ware for Science, San Diego, California, USA).
Results
Thiazacridine derivatives inhibit the proliferation of human colon
carcinoma in HCT-8 cells
Human colon carcinoma HCT-8 cells were treated with 2.5, 5 and
10 μg/ml of ATZD for 12- and/or 24-h and analysed in three different
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a HCT-8 cells. A and B — the inhibition of cell proliferation was determined using the
— the inhibition of cell proliferation was also determined using ﬂow cytometry and
he mean values±S.E.M. from three independent experiments performed in duplicate.
bstance. Amsacrine (PC, m-AMSA, 0.3 μg/ml) was the positive control. For the ﬂow cy-
e negative control using an ANOVA followed by a Student Newman–Keuls test.
Table 1
The effect of thiazacridine derivatives on the cell cycle distribution on human colon
HCT-8 cells.
Drug Concentration
(μg/ml)
Cell cycle distribution (%)
Sub-G1 G1/G0 S G2/M
After 12-h incubation
NC – 1.8±0.1 62.8±0.8 12.5±0.3 15.7±0.4
PC 0.3 1.5±0.4 32.5±1.7⁎ 20.3±2.4⁎ 40.5±2.1⁎
AC-4 2.5 3.8±0.5⁎ 58.2±1.7 13.8±0.9 19.7±0.8⁎
5 4.4±0.3⁎ 57.0±1.1 15.2±0.5 17.4±1.3
10 9.9±1.1⁎ 55.2±2.7 14.5±0.6 12.9±0.9
AC-7 2.5 2.4±0.4 58.3±1.2 13.5±0.6 19.2±0.5⁎
5 5.0±0.6⁎ 57.8±1.3 15.3±1.0 16.2±0.4
10 8.4±0.9⁎ 58.1±1.6 15.3±1.4 12.2±0.6
AC-10 2.5 3.7±0.5⁎ 57.6±1.6 14.1±0.5 19.9±0.5⁎
5 5.3±0.6⁎ 58.2±1.2 14.4±0.3 17.6±0.7
10 6.9±0.5⁎ 58.4±1.3 13.5±0.6 16.7±0.9
AC-23 2.5 3.3±0.8 58.4±1.0 14.7±1.0 16.6±0.3
5 4.6±1.0⁎ 57.6±0.7 16.6±1.1 13.9±0.5
10 8.1±0.8⁎ 60.5±0.3 13.0±0.8 11.9±0.5⁎
After 24-h incubation
NC – 4.7±0.4 59.6±0.8 14.4±0.8 16.0±0,3
PC 0.3 8.1±1.1⁎ 27.8±1.6⁎ 24.0±2.3⁎ 26.3±1.0⁎
AC-4 2.5 13.9±1.5⁎ 55.2±0.8 15.1±1.1 17.5±0.9
5 24.7±2.2⁎ 51.8±0.9⁎ 15.1±0.9 3.9±0.8⁎
10 43.3±1.5⁎ 44.0±1.3⁎ 10.0±0.5⁎ 3.7±0.7⁎
AC-7 2.5 10.9±0.8⁎ 55.7±1.5 14.9±0.4 11.6±0.4⁎
5 13.7±1.4⁎ 54.9±3.3⁎ 13.6±0.7 9.8±0.7⁎
10 26.6±3.6⁎ 54.6±3.4⁎ 8.9±0.5⁎ 5.2±0.7⁎
AC-10 2.5 26.8±0.7⁎ 52.6±2.3⁎ 14.7±0.8 10.8±1.0⁎
5 27.1±1.0⁎ 49.1±3.1⁎ 14.3±0.6 9.7±1.1⁎
10 37.5±1.4⁎ 48.8±1.8⁎ 10.2±0.5⁎ 4.7±0.5⁎
AC-23 2.5 12.1±2.0⁎ 56.3±1.9 12.5±0.5 10.8±1.4⁎
5 24.4±2.1⁎ 55.8±3.3 11.1±0.7 9.8±1.2⁎
10 28.9±2.0⁎ 52.2±3.5⁎ 6.4±0.6⁎ 4.5±0.4⁎
The data are presented as the mean values±S.E.M. from three independent experiments
performed in duplicate. The negative control was treated with the same vehicle (NC, 0.1%
DMSO) that diluted the tested substance. Amsacrine (PC,m-AMSA) served as the positive
control. Five thousand events were analysed for the ﬂow cytometry analysis in each
experiment.
⁎ pb0.05 compared to negative control by ANOVA followed by a Student Newman–
Keuls test.
Fig. 4. The effect of thiazacridine derivatives on the cell morphology of human colon carcino
microscopy after a 24-h incubation with AC-4, AC-7, AC10 and AC23 at concentrations of 2
(A) was treated with the same vehicle (0.1% DMSO) that diluted the tested substance. Ams
show the apoptotic bodies and the non-continuous arrows indicate nuclear fragmentation.
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a concentration- and time-dependent manner.
After a 12-h incubation, cell proliferation was reduced at higher
concentration tested, which was conﬁrmed by trypan blue dye exclu-
sion and propidium iodide exclusion (pb0.05, Figs. 2A, C). After a
24-h incubation, ATZD reduced cell number (pb0.05) at all concen-
trations tested using trypan blue dye exclusion (Fig. 2B), propidium
iodide exclusion (Fig. 2D) and BrdU incorporation (Fig. 3). m-AMSA,
the positive control, also reduced HCT-8 cell proliferation.
Thiazacridine derivatives preferentially caused human colon carcinoma
HCT-8 cells to transition from the G2/M phase to DNA fragmentation
The effects that these ATZD had on cell cycle progression were
evaluated using ﬂow cytometry after 12- and 24-h. All DNA that was
sub-diploid in size (sub-G1) was considered to be caused by inter-
nucleosomal DNA fragmentation. Table 1 indicates the cell cycle distri-
bution obtained. After a 12-h incubation, the ATZD treated with AC-4,
AC-7 and AC-10 (2.5 μg/ml) caused a small increase in the number of
cells in the G2/M phase compared with the negative control (15.7%,
pb0.05). For the ATZD-treated cells, the percentage of cells in the
G2/M phase were 19.7%, 19.2% and 19.9%, for AC-4, AC-7 and AC-10,
respectively. After a 24-h incubation, the cells in the G0/G1 and S
phases remained mostly unchanged; however, there were fewer
cells in the G2/M phase. Additionally, all ATZD caused signiﬁcant
internucleosomal DNA fragmentation at all of the concentrations test-
ed (pb0.05), which implies that ATZD preferentially caused cells from
the G2/M phase to transition into sub-G1. Cells treated with m-AMSA
served as the positive control, and had an increased number of cells
in the G2/M interval and a signiﬁcant amount of internucleosomal
DNA fragmentation.
Thiazacridine derivatives induce apoptosis in human colon carcinoma
HCT-8 cells
After 12- and 24-h incubations, the effects of ATZD were evaluated
based on cell morphology using hematoxylin–eosin and acridinema HCT-8 cells. The cells were stained with hematoxylin-eosin and analysed by optical
.5 (C, F, I, M), 5 (D, G, J, N) and 10 μg/ml (E, H, L, O), respectively. The negative control
acrine (m-AMSA, 0.3 μg/ml) served as the positive control (B). The continuous arrows
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Fig. 5. The effect of thiazacridine derivatives on the viability of human colon carcinoma HCT-8 cells. A and B — cell viability (viable cells – white bar; apoptotic cells – grey bar; and
necrotic cells – black bar) was determined by ﬂuorescence microscopy using acridine orange/ethidium bromide after 12- and 24-h incubations, respectively. The data are presented
as the mean values±S.E.M. from three independent experiments performed in duplicate. The negative control was treated with the same vehicle (NC, 0.1% DMSO) that diluted the
tested substance. Amsacrine (PC, m-AMSA, 0.3 μg/ml) served as the positive control. *, pb0.05 compared to negative control by ANOVA followed by a Student Newman–Keuls test.
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Fig. 6. The effect of thiazacridine derivatives on the viability of human colon carcinoma HCT-8 cells. A and B — the integrity of the cell membranes was determined by ﬂow cytom-
etry using propidium iodide after 12- and 24-h incubations, respectively. C and D— the mitochondrial membrane potential was determined by ﬂow cytometry using rhodamine 123
after 12- and 24-h incubations, respectively. The data are presented as the mean values±S.E.M. from three independent experiments performed in duplicate. The negative control
was treated with the same vehicle (NC, 0.1% DMSO) that diluted the tested substance. Amsacrine (PC,m-AMSA, 0.3 μg/ml) served as the positive control. Five thousand events were
analysed for the ﬂow cytometry analysis in each experiment. *, pb0.05 compared to the negative control using an ANOVA followed by a Student Newman–Keuls test.
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Fig. 7. The effect of thiazacridine derivatives on the viability of human colon carcinoma
HCT-8 cells. A — the cell viability was determined by ﬂow cytometry using Annexin V–
PE. B — the activity of caspase 3/7 was determined by ﬂow cytometry using propidium
iodide and Flica. The data are presented as the mean values±S.E.M. from three inde-
pendent experiments performed in duplicate after a 24-h incubation. The negative
control was treated with the same vehicle (NC, 0.1% DMSO) that diluted the tested sub-
stance. Doxorubicin (PC, 0.3 μg/ml) was the positive control. For the ﬂow cytometry
analysis, 5000 events were analysed in each experiment. *, pb0.05 compared to the
negative control using an ANOVA followed by a Student Newman–Keuls test.
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brane and the mitochondrial membrane potential were also deter-
mined by ﬂow cytometry. Additionally, after a 24-h incubation,
phosphatidylserine externalisation and caspase 3/7 activation were
measured by ﬂow cytometry.
After a 12-h incubation, HCT-8 cells either treated or untreatedwith
ATZD, were tested at all concentrations and presented slight morpho-
logical changes (data not shown). On the other hand, after a 24-h incu-
bation, morphological examination of HCT-8 cells showed severe
drug-mediated changes. The hematoxylin–eosin stained HCT-8 cells
treated with ATZD presented a morphology consistent with apoptosis,
including a reduction in cell volume, chromatin condensation and nu-
clei fragmentation (Fig. 4). The acridine orange/ethidium bromide
stained and treated cells also displayed a morphology consistent with
apoptosis, in a time- and concentration-dependent manner (pb0.05,
Fig. 5). m-AMSA, served as the positive control, which also induced
morphological changes consistent with apoptosis.
The integrity of the cell membrane is a parameter of cell viability
that differs between apoptotic and necrotic cells. After 12- or 24-h
of exposure, ATZD induced a slight disruption in the plasmatic mem-
brane, which was only observed at the higher concentrations tested
(Figs. 6A, B). As cited above, the internucleosomal DNA fragmenta-
tion was markedly increased in ATZD-treated cells (pb0.05, Table 1).
Both of these modiﬁcations are characteristics of apoptotic cells. In
addition, ATZD induced mitochondrial depolarisation in a time- and
concentration-dependent manner (pb0.05, Figs. 6C, D).m-AMSA served
as the positive control, which also induced mitochondrial depolarisation
and DNA fragmentation without affecting the membrane's integrity.
In addition, phosphatidylserine externalisation (AC-4 andAC-10 at
concentrations of 2.5 and 5 μg/ml) and caspase 3/7 activation (AC-4,
AC-10 and AC-23 at concentrations of 5 and 10 μg/ml) weremeasured
in ATZD-treated cells after a 24-h incubation. Phosphatidylserine
exposure (pb0.05, Fig. 7A) and an increase in caspase 3/7 activation
(pb0.05, Fig. 7B) were also observed, suggesting that a caspase-
dependent apoptotic cell death had occurred. Doxorubicin served as
the positive control and also induced phosphatidylserine exposure
and increased caspase 3/7 activation.Thiazacridine derivatives inhibits DNA topoisomerase I action
Because ATZD interact with DNA, they are potential topoisomer-
ase inhibitors. The effect of ATZD on DNA topoisomerase activity
was evaluated in a yeast-based assay and in a cell-free assay.
First, the effects of ATZDwere evaluated using a drop test assay in a
mutant strain of S. cerevisiae that was defective in topoisomerase type
I (Fig. 8). The type IB topoisomerases (topoisomerase 1 in yeast) relax
both positively and negatively supercoiled DNA, whereas type IA
topoisomerases (topoisomerase 3 in yeast) preferentially relax nega-
tively supercoiled DNA. At a concentration of 50 μg/ml, the ATZD
were more resistant in yeast mutants that lacked topoisomerase 1
(Top1Δ) activity compared with the wild-type strain (BY-4741), indi-
cating that these molecules may induce lesions in topoisomerase 1. In
ATZD at higher concentration (100 μg/ml), the Top1Δ mutant was
more sensitive than thewild-type strain, which indicates that an addi-
tional cytotoxicity mechanism (i.e., interaction with topoisomerase II)
may be involved. Moreover, the strain without topoisomerase 3, but
with topoisomerase 1, (Top3Δ), was more sensitive to the ATZD,
with the exception of AC-23. m-AMSA served as the positive control,
which showed similar effects.
In addition, the effect of ATZD on topoisomerase I activity was
evaluated in a cell-free system. Puriﬁed human DNA topoisomerase I
was incubated with ATZD (50 and 100 μg/ml) in the presence of
supercoiled plasmid DNA; the products of this reactionwere subjected
to electrophoresis on agarose gels to separate the closed and open cir-
cular DNAs. Relaxation of the DNA strand was inhibited in both of theconcentrations tested (Fig. 9). CPT served as the positive control be-
cause it also inhibits DNA topoisomerase I.
Thiazacridine derivatives do not cause genotoxicity or inhibit telomerase
activity in human lymphocytes
The genotoxicity of ATZD (AC-4, AC-7, AC-10 and AC-23) was
evaluated in human lymphocyte cultures using an alkaline comet
assay at concentrations of 2.5, 5 and 10 μg/ml. The genotoxicity of
ATZD (AC-4 and AC-10) was also evaluated in human lymphocyte
cultures using a chromosome aberration assay at concentrations of
2.5, 5 and 10 μg/ml. The ability of ATZD (AC-4 and AC-10) to inhibit
telomerase action was performed using a pan telomeric probe at a
concentration of 2.5 μg/ml. None of the ATZD showed genotoxic ac-
tivity or anti-telomerase activity at any experimental concentrations
tested (data not shown). Doxorubicin served as the positive control,
and demonstrated potent genotoxic activity.
Discussion
The present work demonstrates the mechanism by which ATZD
(AC-4, AC-7, AC-10 and AC-23) are cytotoxic in human colon carcino-
maHCT-8 cells. As cited above, these agents were recently synthesised
as a novel class of solid tumour-selective cytotoxic agents. These ATZD
exhibit a relatively high cytotoxicity in colon carcinoma (HCT-8,
HCT-15, SW-620 and COLO-205), prostate carcinoma (PC-3 and
DU-145), ovarian carcinoma (OVCAR-8), melanoma (UACC-62 and
MDA-MB-435) and glioblastoma (SF-295) tumour cell lines. However,
these compounds were not active in leukaemia (HL-60, K-562 and
Fig. 8. The sensitivity of a wild-type strain of Saccharomyces cerevisiae and mutants with defective topoisomerases. The sensitivity of topoisomerases type I to thiazacridine deriv-
atives was determined by a drop test assay. A suspension of S. cerevisiae cells in the exponential phase of growth was treated for 24-h in the absence or in the presence of
thiazacridine derivatives at the indicated concentrations. The diluted cell cultures (107–103 from left to right) were spotted on YPD agar plates. Amsacrine (m-AMSA) served as
the positive control. BY-4741: Wild-type strain; top1Δ: without topoisomerase 1; and top3Δ: without topoisomerase 3.
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mal lymphoblast (PBMC) cells (Barros et al., 2012). Here, we demon-
strate the effects of ATZD on cell proliferation, cell cycle progress and
apoptotic-induction using HCT-8 cells as a model. Studies in a
yeast-based assay and a cell-free assay examine how ATZD interfere
in topoisomerase I activity.
The ATZD inhibit human colon carcinomaHCT-8 cell proliferation in
a concentration- and time-dependent manner, and their cytotoxic ac-
tivity was assessed using different assays. Previously, we demonstrated
that ATZD exhibited relatively high cytotoxicity against colon carcino-
mas and that the highlight of these ATZD was their selectivity toward
solid tumours because these ATZD were not active in leukaemias or
normal lymphoblasts (Barros et al., 2012). The pyrazoloacridines,
bisannulated acridines, aminoderivatives of azapyranoxanthenone
and pyranoisoﬂavones have also been cited as solid tumour-selective
cytotoxic agents (Gao et al., 2011; Kolokythas et al., 2006; Sebolt, et
al., 1987; Thale et al., 2002). Therefore, this feature is noteworthy but
the mechanisms accounting for this selectivity are poorly understood.
The population of cells in the G2/M phase was shifted to the sub-G1
population in ATZD-treated HCT-8 cells, whilst few changes occurred
in the population of cells in the G0/G1 or S phases. This indicates that
the ATZD preferentially guide cells from the G2/M phase into apopto-
sis. Manipulating the regulatory events at this checkpoint is a promis-
ing approach that will improve the efﬁciency of cytotoxic drugs and
overcome drug resistance (Links et al., 1998). In addition, HCT-8
cells treated with ATZD presented typical hallmarks of apoptosis. Se-
lective apoptosis, the deletion of certain cells in tissues without con-
comitant inﬂammation, is advantageous in tissue homeostasis. The
induction of apoptosis is one of themainmechanisms that inhibit can-
cer growth and proliferation and is used by several antitumor agents
(Los et al., 2003; Schultz and Harrington, 2003). Moreover, ATZDtreatment induces mitochondrial depolarisation, phosphatidylserine
exposure and an increase in caspase 3/7 activation, which suggests
that ATZD treatment leads to a caspase-dependent apoptotic cell
death. Caspases play an essential role in apoptosis (Fan et al., 2005;
Kitazumi and Tsukahara, 2011): these caspases are responsible for
the cleavage of cellular proteins, such as cytoskeletal components,
which leads to the morphological changes previously observed in
the cells that undergo apoptosis (Kothakota et al., 1997).
The mechanism by which acridine and thiazolidine derivatives act
has been continuously researched. Thiazolidine derivatives activate
peroxisome proliferator-activated receptors (Barros et al., 2010).Mean-
while, acridine derivatives used in cancer chemotherapy have biological
targets, such as DNA topoisomerases I and/or II, telomerase/telomeres
and kinases (Castillo-González et al., 2009; Guo et al., 2009; Oppegard
et al., 2009). Our understanding of ATZD's cytotoxic mechanisms have
been limited to results from double stranded-DNA biosensors and
single stranded-DNA solutions, which show a positive interaction
with these ATZD that couple acridine and thiazolidine (Barros et
al., 2012). Here, we demonstrate that ATZD inhibit DNA topoisomer-
ase I activity.
The cytotoxicity of DNA topoisomerase I inhibitors is caused by
blocking DNA topoisomerase I cleavage complexes or by inhibiting
DNA topoisomerase I catalytic activity. Then, DNA topoisomerase I
inhibitors work by stabilising the DNA topoisomerase I cleavage com-
plexes, which cause DNA damage (Hsiang et al., 1989; Pommier et al.,
1998; Stewart et al., 1998). Because malignant cells often contain
greater amounts of DNA topoisomerase I than normal cells, tumour
cells should be more sensitive to the toxic effects of these inhibitors.
The malignant cells that often contain great amounts of DNA topo-
isomerase I include colon adenocarcinoma, several types of non-
Hodgkin's lymphoma, leukaemias, melanoma and carcinomas of the
Fig. 9. The inhibition of topoisomerase I-mediated DNA supercoiling in the presence of thiazacridine derivatives. The supercoiled DNA (250 ng) was incubated with 4 units of topo-
isomerase I in the presence or absence of thiazacridine derivatives at the indicated concentrations. The negative control was treated with the same vehicle that diluted the tested
substance. Camptothecin (CPT) served as the positive control. The DNA was analysed by electrophoresis using a 1% agarose gel. The gels were stained with ethidium bromide and
photographed under UV light.
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selective cytotoxic effects of ATZD. However, the exact mechanism of
this selective antitumor activity remains to be determined.
Previous studies have reported that some acridine and thiazolidine
derivatives are somatic- and germ-cell mutagenic agents capable of
inducing both numerical and structural chromosome aberrations in
vitro and in vivo (Attia, 2008; Attia, in press; Kao-Shan et al., 1984;
Nishi et al., 1989). These compounds are highly cytotoxic/genotoxic
to normal lymphocyte cells. Therefore, to improve our understanding
of the ATZD's cytotoxic actions, we assessed their genotoxic effects in
human peripheral lymphocytes. Previously, the cytotoxicity of these
compounds was assessed against normal lymphocyte cells (Barros et
al., 2012); however, the genotoxicity had not been investigated. The
genotoxic effects of ATZD were determined using an alkaline comet
assay and a chromosome aberration assay; the anti-telomerase activ-
ity was determined using a pan telomeric probe. In our studies, none
of these ATZD agents showed genotoxicity and/or anti-telomerase ac-
tivity in cultured human lymphocytes at the experimentally tested
concentrations. Therefore, unlike the acridine and thiazolidine deriva-
tives, ATZD did not cause cytotoxicity, genotoxicity and the inhibition
of telomerase activity in human lymphocytes.
In this manuscript, we show that the ATZD are solid tumour-
selective cytotoxic agents that inhibit DNA topoisomerase I activity
and induce tumour cell death through caspase-dependent apoptosis
pathways without causing genotoxicity in human lymphocytes.
These data conﬁrm that these ATZD are promising anticancer drugs.Conﬂicts of interest
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